Physician profile
Paul Edwin Lemanski
NPI 1831190016
$4,851.52
in general payments reported to CMS, 2019-2025
28 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $375 · 2021: $758 · 2022: $759 · 2023: $996 · 2024: $570 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.18 |
| Education | $213.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,073.02 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $735.69 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $410.03 | 2021-2025 | |
| Glaxosmithkline, LLC. | $396.30 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $351.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $294.23 | 2019-2023 | Breztri |
| Esperion Therapeutics, INC. | $189.50 | 2020-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $175.07 | 2019-2022 | |
| Pfizer INC. | $165.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.97 | 2019-2023 | |
| Amarin Pharma, INC. | $135.84 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $117.65 | 2019-2023 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $115.75 | 2020-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $105.37 | 2021-2025 | |
| Exact Sciences Corporation | $85.80 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $54.57 | 2019-2020 | |
| Eisai INC. | $46.51 | 2019-2022 | |
| Ibsa Pharma INC. | $41.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $40.09 | 2019-2021 | |
| Abbvie INC. | $35.99 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.01 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $22.90 | 2023 | Quviviq |
| Abbott Laboratories | $21.65 | 2023 | Freestyle Libre 3 |
| Agepha Pharma Fz LLC | $19.44 | 2025 | Lodoco |
| Circassia INC. | $16.55 | 2019 | |
| Seqirus USA INC | $12.76 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lemanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.